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Inflammatory mouse Ly6C
high monocyte subset and its
human counterpart, defined as CD14
+ CD16
-, represent a
valuable cellular target for innovative immunotherapeutic
strategies against immune-mediated inflammatory disor-
ders (IMID). However, delivery systems able to differen-
tially target both subsets in vivo are still missing as well
as demonstration for efficient immuno-modulation. The
present work aims at providing evidences for the selective
delivery of a siRNA-containing lipid formulation to the
Ly-6C
high monocyte population and at evaluating the
therapeutic potential of targeting this subset as well as
their human counterpart for immuno-intervention in a
prototype IMID like rheumatoid arthritis (RA). The pre-
B-cell colony enhancing factor (PBEF/visfatin/Nampt) is
an essential enzyme in the NAD biosynthetic pathway
that exerts a key role in the persistence of inflammation
through the induction of the expression of the TNF-a
and IL-6 pro-inflammatory cytokines and is highly
expressed in patients with a variety of IMID. Mice with
collagen-induced arthritis (CIA) display Ly-6C
high mono-
cytosis in the circulation that infiltrate into the inflamed
joints. The systemic delivery of siRNAs formulated with
the cationic liposome DMAPAP provides specific and
functional down-regulation of PBEF within inflammatory
monocytes. Moreover, decreased production of the
PBEF-induced pro-inflammatory cytokines TNF-a and
IL-6 was evidenced in both mouse and human inflamma-
tory monocytes. PBEF gene silencing within Ly-6C
high
monocytes resulted in reduced disease severity in mice
with CIA, associated with an overall systemic immuno-
modulation of the effector T cell balance. These results
identify PBEF as a critical target to modulate autoim-
mune responses and inflammation in arthritis and pro-
vide novel evidence that silencing of a master gene
within inflammatory monocytes is a promising strategy
for future therapeutic intervention in the context of
IMID.
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